Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) generates a steady flow of news as it pursues its strategy in value-based community oncology care. Founded in 2007, the company describes itself as one of the largest value-based oncology groups in the United States, with over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. News about TOI often highlights how it combines specialized cancer care with value-based payment models and community-based delivery.
Investors and observers following TOI news can expect updates on financial performance, guidance, and outlook, including revenue mix across patient services, dispensary, and capitation arrangements. The company regularly issues press releases on quarterly results, non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow, and changes to its financial guidance. These items are often accompanied by management commentary on operational trends in areas like pharmacy, dispensary, and delegated contracts.
TOI’s news flow also covers clinical and operational initiatives. Examples include participation in CMS programs such as the Enhancing Oncology Model, where the company has reported Medicare savings and quality scores, as well as the launch of centers of excellence, such as a Lung Cancer Center of Excellence in Florida. Announcements may describe programs like its High Value Cancer Care initiative, 24/7 symptom management support, and efforts to reduce avoidable emergency department visits and admissions.
Another recurring theme in TOI news is technology and leadership. The company has reported partnerships to co-develop AI-enabled administrative automation, and it has announced leadership promotions and board changes that relate to technology strategy, people operations, and financial oversight. For readers tracking TOI, this news page offers a way to follow developments in value-based oncology care, operational efficiency initiatives, and governance updates over time.
The Oncology Institute (NASDAQ: TOI) reported Q4 2025 revenue of $142.0M (+41.6%) and full-year 2025 revenue of $502.7M (+27.8%), with gross profit of $76.4M for 2025 (+41.6%).
Q4 adjusted EBITDA was $0.15M, full-year adjusted EBITDA was $(12.4)M, net loss for 2025 was $(60.6)M, and cash totaled $33.6M as of Dec 31, 2025. 2026 guidance: revenue $630–650M, gross profit $97–107M, adjusted EBITDA $0–9M, free cash flow $(15)–5M.
The company expects ~$150M in capitated revenue in 2026 and anticipates Q1 2026 adjusted EBITDA of $(1)M to $(3)M due to seasonality and reimbursement timing.
The Oncology Institute (NASDAQ: TOI) will release fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, followed by a conference call the same day at 5:00 p.m. ET. Investors can join via phone or webcast.
A replay will be available two hours after the call through Thursday, March 19, 2026 using the provided passcode; international dial-in and webcast details are available on the investor relations site.
The Oncology Institute (NASDAQ: TOI) announced executive participation in three investor conferences in March 2026. Presentations include Jefferies Healthcare Services Innovation & Technology Summit and Leerink Global Healthcare Conference on March 9 in Miami, and Oppenheimer MedTech & Services Conference (virtual) on March 16.
Presenters include Dr. Daniel Virnich, CEO, and Rob Carter, CFO; webcasts and replays will be available via the company Investor Relations site.
The Oncology Institute (NASDAQ: TOI) appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026.
Ms. Tzoumakas brings more than two decades of executive leadership in oncology, pharmacy services and healthcare operations, currently serving as CEO of VytlOne National Pharmacy Services and with prior CEO and board experience.
The Oncology Institute (NASDAQ: TOI) reaffirmed 2025 guidance and provided a preliminary 2026 outlook on Jan 12, 2026. For 2026 the company expects total revenue of $630 million to $650 million, ~28% growth from the 2025 midpoint, including about $150 million of Capitation revenue.
TOI forecasts Adjusted EBITDA of $0 million to $9 million for 2026 (midpoint would be its first full year of Adjusted EBITDA profitability as a public company) and says profitability from newly onboarded delegated contracts will build through 2026 with fuller economics in 2027.
Longer term, TOI targets ~20% annual revenue growth through 2028, expects Capitation and Dispensary to be ~30% and 50% of revenue respectively, and projects margins expanding to the mid-single-digit range by 2028.
The Oncology Institute (NASDAQ: TOI) announced on Jan 9, 2026 the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer.
Panda brings more than 25 years of IT, digital transformation, cybersecurity, and enterprise software experience, with prior leadership roles at Cisco and Infosys; he will lead TOI’s technology strategy, including AI-enablement and enterprise data privacy and security practices. Mariano, with 18 years in people operations, joined TOI in 2022 and will oversee HR Operations, Total Rewards, Learning and Development, and Talent Acquisition.
CEO Dr. Daniel Virnich said the promotions support TOI’s growth and its focus on technology-enabled, value-based community cancer care.
The Oncology Institute (NASDAQ: TOI) announced that Mark Stolper joined its Board of Directors, effective January 2, 2026. Stolper currently serves as Executive Vice President and Chief Financial Officer of RadNet (NASDAQ: RDNT), a role he has held since 2004, and has prior board experience at public and private healthcare companies including 21st Century Oncology Holdings.
The company highlighted Stolper's expertise in capital markets, fundraising, strategic financial planning and payor strategy as supporting TOI's next phase of growth. Stolper commented that he expects TOI to pursue continued growth and profitability while focusing on cost-effective cancer care and improved patient outcomes.
The Oncology Institute (NASDAQ: TOI) announced that Gabe Ling resigned from the Board of Directors, effective December 1, 2025. The company said a formal search has begun to add independent directors with healthcare, clinical, and value-based care expertise.
The board emphasized thanks for Ling’s service during the company’s early public-market years and stated a continuing focus on strengthening governance and recruiting strategic, experienced members to support long-term growth.
The Oncology Institute (NASDAQ: TOI) reported Q3 2025 results and raised full‑year guidance on Nov 13, 2025. Consolidated revenue was $136.6M, up 36.7% year‑over‑year; gross profit was $18.9M, up 31.7%. Retail pharmacy set fill records, contributing $75.9M revenue and $12.8M gross profit in Q3. Net loss was $16.5M and basic/diluted loss per share was $0.14. Adjusted EBITDA improved to $(3.5)M in Q3; cash and cash equivalents were $27.7M at quarter end.
TOI updated 2025 guidance: revenue to $495–505M (from $460–480M) and Adjusted EBITDA to $(11)–$(13)M (from $(8)–$(17)M); Q4 Adjusted EBITDA is expected around $0–$2M. The company noted continued organic growth in Florida and Oregon and a new CAO hire for operations and AI enablement. A conference call and webcast were scheduled for Nov 13, 2025 at 5:00 p.m. ET.
Ascertain and The Oncology Institute (NASDAQ: TOI) announced a co-development to deploy a “near-touchless” prior authorization workflow using Ascertain’s Unified Payer Portal.
The joint team moved from signed statement of work to a live early-stage deployment in eight weeks, with the system live since September 2025. Pilot sites saw a >80% reduction in office-visit authorization submission time and the program freed hundreds of staff hours each week. The portal now processes prior authorizations across TOI’s 100+ clinics and affiliates. TOI estimates the initiative could yield up to $2 million in operating expense savings in 2026 as the solution scales to additional authorization types.